Correlation Between Opus Genetics, and CERo Therapeutics

Can any of the company-specific risk be diversified away by investing in both Opus Genetics, and CERo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Opus Genetics, and CERo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Opus Genetics, and CERo Therapeutics Holdings, you can compare the effects of market volatilities on Opus Genetics, and CERo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Opus Genetics, with a short position of CERo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Opus Genetics, and CERo Therapeutics.

Diversification Opportunities for Opus Genetics, and CERo Therapeutics

0.2

Correlation Coefficient

Opus Genetics,  CERo Therapeutics

Modest diversification

The 3 months correlation between Opus and CERo is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Opus Genetics, and CERo Therapeutics Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CERo Therapeutics and Opus Genetics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Opus Genetics, are associated (or correlated) with CERo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CERo Therapeutics has no effect on the direction of Opus Genetics, i.e., Opus Genetics, and CERo Therapeutics go up and down completely randomly.

Pair Corralation between Opus Genetics, and CERo Therapeutics

Considering the 90-day investment horizon Opus Genetics, is expected to under-perform the CERo Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Opus Genetics, is 8.16 times less risky than CERo Therapeutics. The stock trades about -0.15 of its potential returns per unit of risk. The CERo Therapeutics Holdings is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  1.40  in CERo Therapeutics Holdings on December 5, 2024 and sell it today you would lose (0.01) from holding CERo Therapeutics Holdings or give up 0.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	95.24%
Values	Daily Returns

Opus Genetics,  vs.  CERo Therapeutics Holdings

Opus Genetics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Opus Genetics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

CERo Therapeutics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in CERo Therapeutics Holdings are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, CERo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Opus Genetics, and CERo Therapeutics

The main advantage of trading using opposite Opus Genetics, and CERo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Opus Genetics, position performs unexpectedly, CERo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will offset losses from the drop in CERo Therapeutics' long position.

The idea behind Opus Genetics, and CERo Therapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.